Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

Janssen files abiraterone acetate NDS with Health Canada for metastatic, advanced prostate cancer

Janssen Inc. has filed a New Drug Submission (NDS) to Health Canada for the investigational drug abiraterone acetate administered with prednisone for the treatment of metastatic, advanced prostate cancer in patients who have received prior chemotherapy containing a taxane. Submissions for abiraterone acetate have also been filed with health authorities in the United States and Europe.

23 Dec 2010

Baylor Sammons Cancer Center, Sarah Cannon, and Virginia Cancer join Multiple Myeloma Research Consortium

The Multiple Myeloma Research Consortium (MMRC) today announced that it has expanded its clinical research network to include Baylor Charles A. Sammons Cancer Center (Dallas, TX), Sarah Cannon /Research Institute (SCRI, Nashville, TN) and Virginia Cancer Specialists (Fairfax, VA). These new centers join the 13 existing MMRC Member Institutions in promoting and facilitating collaborative research and accelerating drug development in multiple myeloma, an incurable blood cancer.

23 Dec 2010

Pfizer seeks FDA and EMA approval for expanded use of Prevnar 13 for pneumococcal disease

Pfizer Inc today announced that it has submitted supplemental applications to both the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to expand the use of Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) to adults 50 years of age and older for the prevention of pneumococcal disease caused by the 13 serotypes contained in the vaccine.

23 Dec 2010

Merck announces FDA approval for GARDASIL against HPV-related anal cancer

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for the prevention of anal cancer caused by human papillomavirus (HPV) types 16 and 18 and for the prevention of anal intraepithelial neoplasia (AIN) grades 1, 2 and 3 (anal dysplasias and precancerous lesions) caused by HPV types 6, 11, 16 and 18, in males and females 9 through 26 years of age.

23 Dec 2010

FDA issues CRL to Cumberland's Acetadote sNDA for non-acetaminophen acute liver failure

Cumberland Pharmaceuticals Inc. announced today that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding its supplemental new drug application (sNDA) for Acetadote® (acetylcysteine) Injection to treat patients with non-acetaminophen induced acute liver failure.

22 Dec 2010

Intellipharmaceutics announces delay of patent approvement to market Protonix drug

Intellipharmaceutics International, today announced that it has notified the U.S. Food and Drug Administration that it has not received notification, as provided for under the Hatch-Waxman Act, of any patent infringement proceedings by the brand owner, Wyeth Pharmaceuticals, a wholly-owned subsidiary of Pfizer, for its application to market a generic of Wyeth's Protonix® tablets.

22 Dec 2010

Vertex announces modification of telaprevir and VX-222 combination Phase 2 trial for treatment of HCV

Vertex Pharmaceuticals Incorporated today announced a modification of its Phase 2 clinical trial evaluating 12-week, response-guided regimens of its lead investigational hepatitis C virus (HCV) protease inhibitor, telaprevir, in combination with its lead investigational HCV polymerase inhibitor, VX-222.

22 Dec 2010

Takeda completes settlements in patent litigation over generic ACTOS, ACTOplus met, and duetact ANDAs

Takeda Pharmaceutical Company Limited ("Takeda") today announced that Takeda and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc. ("TPNA"), have completed settlements with all defendants in patent litigation brought against the companies in response to their Abbreviated New Drug Applications ("ANDAs") for generic ACTOS® (pioglitazone HCl), ACTOplus met® (pioglitazone HCl and metformin HCl), and duetact® (pioglitazone HCl and glimepiride).

22 Dec 2010

Contamination with potential disease-causing bacteria is commonly found on hands of anesthesia providers

Contaminating bacteria are very commonly found on the hands of anesthesia providers, with high rates of transmission to the surgical field during operations, reports a study in the January issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

22 Dec 2010

Pro-Pharmaceuticals, Mount Sinai collaborate to evaluate anti-fibrotic effects of Galectin-targeting compounds

Pro-Pharmaceuticals, Inc., the leading developer of Galectin therapeutics to treat cancer and fibrosis, today announced it has entered into a new research collaboration with Mount Sinai School of Medicine to evaluate in pre-clinical models, the anti-fibrotic effects of several of the Company's novel, Galectin-targeting compounds.

21 Dec 2010

Investigator to receive AGA-General Mills Bell Institute of Health and Nutrition Research Scholar Award

The American Gastroenterological Association Foundation for Digestive Health and Nutrition announced that Anisa Shaker, MD, is the recipient of the AGA-General Mills Bell Institute of Health and Nutrition Research Scholar Award in Gut Physiology and Health.

21 Dec 2010

Researchers present definitive explanation of how fibrotic cells destroy human liver

In the latest of a series of related papers, researchers at the University of California, San Diego School of Medicine, with colleagues in Austria and elsewhere, present a new and more definitive explanation of how fibrotic cells form, multiply and eventually destroy the human liver, resulting in cirrhosis. In doing so, the findings upend the standing of a long-presumed marker for multiple fibrotic diseases and reveal the existence of a previously unknown kind of inflammatory white blood cell.

21 Dec 2010

Damon Runyon Cancer Research Foundation names first recipients of Frey Award for Breakthrough Scientists

The Damon Runyon Cancer Research Foundation, a non-profit organization focused on supporting innovative early career researchers, named the first recipients of the Dale F. Frey Award for Breakthrough Scientists. This new award provides additional funding to scientists completing a prestigious Damon Runyon Fellowship Award who have greatly exceeded the Foundation's highest expectations and are most likely to make paradigm-shifting breakthroughs that transform the way we prevent, diagnose and treat cancer.

21 Dec 2010

Global Health Partner acquires shares in Stockholm Gastro Center

On September 27, 2010 Global Health Partner acquired shares in Stockholm Gastro Center, a specialist clinic in the field of medical gastroenterology and endoscopy located in Sophiahemmet in Stockholm. 190,476 shares were issued on December 17, 2010 in part payment to the sellers of the clinic.

21 Dec 2010

4SC AG's Phase IIb study evaluates efficacy of vidofludimus in RA patients

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, today reported that it has completed enrolment of its COMPONENT Phase IIb study with vidofludimus, an oral inhibitor of IL-17 release, in rheumatoid arthritis (RA) patients. Data from the trial are expected to be announced in Q2 2011.

20 Dec 2010

Tips to enjoy holiday food and other special parts of the season

While most of us look forward with anticipation to the culinary delights of the holiday season, the decedent buffet can be treacherous territory for those with food-related health concerns.

17 Dec 2010

Astonishing diversity of microbes inhabit the human body

A mounting tide of scientific evidence suggests that the old adage from Aesop's fables - "You are known by the company you keep" - also applies to the trillions of microscopic bacteria and viruses that live on the human body. Humanity's invisible but constant companions - more bacteria hang out on the palms of your hands than there are people on Earth - is the topic of an article in the current edition of Chemical & Engineering News (C&EN), ACS' weekly newsmagazine.

17 Dec 2010

Children's Hospitals and Clinics of Minnesota praises fix of orphan drug discount under 340B program

Families who were facing the prospect of huge increases in the cost of life-saving drugs for their children can breath easier thanks to a new law that will preserve discounts on specialized, so-called "orphan drugs."

17 Dec 2010

MDA awards Repligen $1.4M for research of new compound with therapeutic potential for SMA

The Muscular Dystrophy Association today announced it has awarded $1.4 million in new research funding to the biopharmaceutical firm Repligen of Waltham, Mass., to complete the preclinical work needed to begin human clinical trials of a promising therapeutic compound for spinal muscular atrophy (SMA).

17 Dec 2010

MCSA Tool for colonoscopy trainees to assess cognitive and motor skills

Researchers at the Mayo Clinic in Rochester, have developed a new skills assessment tool for colonoscopy trainees.

15 Dec 2010

Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

Janssen files abiraterone acetate NDS with Health Canada for metastatic, advanced prostate cancer

Baylor Sammons Cancer Center, Sarah Cannon, and Virginia Cancer join Multiple Myeloma Research Consortium

Pfizer seeks FDA and EMA approval for expanded use of Prevnar 13 for pneumococcal disease

Merck announces FDA approval for GARDASIL against HPV-related anal cancer

FDA issues CRL to Cumberland's Acetadote sNDA for non-acetaminophen acute liver failure

Intellipharmaceutics announces delay of patent approvement to market Protonix drug

Vertex announces modification of telaprevir and VX-222 combination Phase 2 trial for treatment of HCV

Takeda completes settlements in patent litigation over generic ACTOS, ACTOplus met, and duetact ANDAs

Contamination with potential disease-causing bacteria is commonly found on hands of anesthesia providers

Pro-Pharmaceuticals, Mount Sinai collaborate to evaluate anti-fibrotic effects of Galectin-targeting compounds

Investigator to receive AGA-General Mills Bell Institute of Health and Nutrition Research Scholar Award

Researchers present definitive explanation of how fibrotic cells destroy human liver

Damon Runyon Cancer Research Foundation names first recipients of Frey Award for Breakthrough Scientists

Global Health Partner acquires shares in Stockholm Gastro Center

4SC AG's Phase IIb study evaluates efficacy of vidofludimus in RA patients

Tips to enjoy holiday food and other special parts of the season

Astonishing diversity of microbes inhabit the human body

Children's Hospitals and Clinics of Minnesota praises fix of orphan drug discount under 340B program

MDA awards Repligen $1.4M for research of new compound with therapeutic potential for SMA

MCSA Tool for colonoscopy trainees to assess cognitive and motor skills

Pittcon Keynote Speaker Highlights eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

Pittcon Keynote Speaker Highlights eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in